PL2897604T3 - Kompozycje do ulepszenia funkcji mózgu - Google Patents
Kompozycje do ulepszenia funkcji mózguInfo
- Publication number
- PL2897604T3 PL2897604T3 PL13773433T PL13773433T PL2897604T3 PL 2897604 T3 PL2897604 T3 PL 2897604T3 PL 13773433 T PL13773433 T PL 13773433T PL 13773433 T PL13773433 T PL 13773433T PL 2897604 T3 PL2897604 T3 PL 2897604T3
- Authority
- PL
- Poland
- Prior art keywords
- compositions
- improvement
- brain function
- brain
- function
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01001—Alpha-amylase (3.2.1.1)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261703163P | 2012-09-19 | 2012-09-19 | |
| SE1200567 | 2012-09-19 | ||
| PCT/SE2013/051098 WO2014046603A1 (en) | 2012-09-19 | 2013-09-19 | Compositions for improvement of brain function |
| EP13773433.1A EP2897604B1 (en) | 2012-09-19 | 2013-09-19 | Compositions for improvement of brain function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2897604T3 true PL2897604T3 (pl) | 2018-10-31 |
Family
ID=49304297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13773433T PL2897604T3 (pl) | 2012-09-19 | 2013-09-19 | Kompozycje do ulepszenia funkcji mózgu |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US9592211B2 (pl) |
| EP (2) | EP2897604B1 (pl) |
| JP (2) | JP6263540B2 (pl) |
| KR (1) | KR102198633B1 (pl) |
| CN (1) | CN104797248B (pl) |
| AU (1) | AU2013318686B2 (pl) |
| CA (1) | CA2884592C (pl) |
| DK (1) | DK2897604T3 (pl) |
| ES (1) | ES2681343T3 (pl) |
| HK (1) | HK1207566A1 (pl) |
| PL (1) | PL2897604T3 (pl) |
| WO (1) | WO2014046603A1 (pl) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2884592C (en) * | 2012-09-19 | 2021-08-31 | Grespo Ab | Compositions for improvement of brain function |
| WO2016083399A1 (en) * | 2014-11-24 | 2016-06-02 | Forschungsgesellschaft Für Arbeitsphysiologie Und Arbeitsschutz E. V. | Alpha-ketoglutarate in combination with glutamate dehydrogenase for treating hyperammonemia |
| US20200253907A1 (en) * | 2017-08-21 | 2020-08-13 | The Regents Of The University Of California | Compositions and Methods for Treating Neurodegenerative Diseases |
| KR20210065120A (ko) | 2018-09-25 | 2021-06-03 | 폰세 드 리온 헬스 데지그네이티드 액티비티 컴퍼니 | 칼슘 알파-케토글루타레이트의 제조 방법 |
| WO2022040022A1 (en) * | 2020-08-18 | 2022-02-24 | St. Jude Children's Research Hospital, Inc. | Use of amylase or maltose to treat or prevent neurodegeneration |
| WO2023200281A1 (ko) * | 2022-04-15 | 2023-10-19 | 재단법인대구경북과학기술원 | 알츠하이머병 또는 경도 인지장애 진단을 위한 비응집성 용해조성물 및 이를 이용한 진단 방법 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2711436B2 (ja) | 1995-02-22 | 1998-02-10 | マルホ株式会社 | アレルギー治療剤及びアレルギー対応食品 |
| AU6221496A (en) | 1995-05-31 | 1996-12-18 | Simon Lodewijk Scharpe | Composition to improve digestibility and utilisation of nutr ients |
| US6372473B1 (en) | 1997-05-28 | 2002-04-16 | Human Genome Sciences, Inc. | Tissue plasminogen activator-like protease |
| JP2001521002A (ja) | 1997-10-24 | 2001-11-06 | コーネル リサーチ ファンデーション インク． | 脳の代謝機能不全のための栄養補充剤 |
| US20010046493A1 (en) | 2000-02-24 | 2001-11-29 | Alex Margolin | Lipase-containing composition and methods of use thereof |
| US20070053895A1 (en) * | 2000-08-14 | 2007-03-08 | Fallon Joan M | Method of treating and diagnosing parkinsons disease and related dysautonomic disorders |
| WO2002060495A1 (en) | 2001-01-09 | 2002-08-08 | Louis Johan Wagenaar | Procedure and composition of treatment and/or care of the eye |
| AR032392A1 (es) | 2001-01-19 | 2003-11-05 | Solvay Pharm Gmbh | Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado. |
| US6689810B2 (en) | 2001-08-21 | 2004-02-10 | Cellular Sciences, Inc. | Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide |
| US7122578B2 (en) | 2001-09-11 | 2006-10-17 | Alain Martin | Method and composition for treating mammalian diseases and injuries which cause pain, erythema, swelling, crusting, ischemia scarring and excess white blood cell infiltration |
| US8076373B2 (en) | 2001-09-11 | 2011-12-13 | North Cell Pharmacetical | Method for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite |
| US7241456B2 (en) | 2002-10-25 | 2007-07-10 | Australian Importers Ltd. | Formulations for topical delivery of bioactive substances and methods for their use |
| JP4265997B2 (ja) | 2004-07-14 | 2009-05-20 | 富士通マイクロエレクトロニクス株式会社 | 半導体装置及びその製造方法 |
| PL369552A1 (pl) * | 2004-08-12 | 2006-02-20 | Sgp & Sons Ab | Preparat farmaceutyczny lub/i żywieniowy lub/i laboratoryjny wzmagający, wspomagający funkcjonowanie komórek nerwowych i układu nerwowego oraz zastosowanie preparatu farmaceutycznego lub/i żywieniowego w procesie ochrony funkcji układu nerwowego oraz zastosowanie preparatu do ochrony wzrostu stymulacji namnażania i zapobiegania apoptozie komórek nerwowych |
| DK1809320T3 (da) * | 2004-10-14 | 2010-11-15 | Cystic Fibrosis Foundation The | Præparater indeholdende lipase, protease og amylase til behandling af pankreatisk insufficiens |
| AU2005316295B2 (en) | 2004-12-17 | 2012-03-22 | Alan B. Cash | Method for extending lifespan and delaying the onset of age-related disease |
| EP1977249A2 (en) * | 2006-01-19 | 2008-10-08 | Entress AB | Method of diagnosis and method of treatment |
| PL226695B1 (pl) | 2006-07-03 | 2017-08-31 | Danuta Kruszewska | Środek do zastosowania w zapobieganiu i/lub hamowaniu kolonizacji Helicobacter pylori, zastosowanie soli kwasu alfa‑ketoglutarowego z metalami alkalicznymi i ziem alkalicznych do wytwarzania środka leczniczego oraz dodatku do żywności do zapobiegania i/lub hamowania kolonizacji Helicobacter pylori |
| ES2557160T3 (es) * | 2006-10-23 | 2016-01-22 | Nestec S.A. | Modulación del aroma y el sabor mediante biotransformación en productos lácteos |
| US8246950B2 (en) * | 2007-02-20 | 2012-08-21 | Aptalis Pharma Limited | Stable digestive enzyme compositions |
| WO2010002972A1 (en) | 2008-07-01 | 2010-01-07 | Curemark, Llc | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
| US20100092447A1 (en) * | 2008-10-03 | 2010-04-15 | Fallon Joan M | Methods and compositions for the treatment of symptoms of prion diseases |
| EA201101519A1 (ru) | 2009-05-11 | 2012-10-30 | БЕРГ БАЙОСИСТЕМЗ, ЭлЭлСи | Способы диагностики метаболических нарушений, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния |
| CN101884631A (zh) | 2009-05-12 | 2010-11-17 | 复旦大学 | 基于α酮戊二酸及其衍生物的抗肿瘤药物 |
| CN102010890B (zh) * | 2009-09-08 | 2013-05-22 | 北京迪迈医学诊断技术有限公司 | 线粒体天门冬氨酸氨基转移酶测定试剂盒 |
| US20110064712A1 (en) * | 2009-09-16 | 2011-03-17 | Daniel Moses Amato | Dietary Supplement Compositions and Methods of Making and Using the Same |
| US9050306B2 (en) | 2010-06-22 | 2015-06-09 | Alan B. Cash | Activation of AMP-protein activated kinase by oxaloacetate compounds |
| KR20130101515A (ko) | 2010-08-23 | 2013-09-13 | 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘, 엘티디. | 위에 활성제를 전달하기 위한 조성물 |
| WO2012078798A1 (en) | 2010-12-07 | 2012-06-14 | Bananalogix, Inc. | Methods of processing organic matter and compositions thereof |
| CA2884592C (en) * | 2012-09-19 | 2021-08-31 | Grespo Ab | Compositions for improvement of brain function |
-
2013
- 2013-09-19 CA CA2884592A patent/CA2884592C/en active Active
- 2013-09-19 EP EP13773433.1A patent/EP2897604B1/en active Active
- 2013-09-19 AU AU2013318686A patent/AU2013318686B2/en active Active
- 2013-09-19 KR KR1020157009161A patent/KR102198633B1/ko active IP Right Grant
- 2013-09-19 DK DK13773433.1T patent/DK2897604T3/en active
- 2013-09-19 US US14/428,841 patent/US9592211B2/en active Active
- 2013-09-19 WO PCT/SE2013/051098 patent/WO2014046603A1/en active Application Filing
- 2013-09-19 ES ES13773433.1T patent/ES2681343T3/es active Active
- 2013-09-19 JP JP2015533015A patent/JP6263540B2/ja active Active
- 2013-09-19 CN CN201380058821.4A patent/CN104797248B/zh active Active
- 2013-09-19 EP EP18178948.8A patent/EP3398594A1/en active Pending
- 2013-09-19 PL PL13773433T patent/PL2897604T3/pl unknown
-
2015
- 2015-08-24 HK HK15108187.9A patent/HK1207566A1/xx unknown
-
2017
- 2017-03-02 US US15/447,974 patent/US20170333372A1/en not_active Abandoned
- 2017-10-25 JP JP2017205991A patent/JP2018048175A/ja active Pending
-
2021
- 2021-01-29 US US17/163,065 patent/US20210154160A1/en active Pending
-
2023
- 2023-10-25 US US18/494,126 patent/US20240065993A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP6263540B2 (ja) | 2018-01-17 |
| US20150297544A1 (en) | 2015-10-22 |
| US9592211B2 (en) | 2017-03-14 |
| HK1207566A1 (en) | 2016-02-05 |
| JP2018048175A (ja) | 2018-03-29 |
| KR20150058292A (ko) | 2015-05-28 |
| WO2014046603A1 (en) | 2014-03-27 |
| EP3398594A1 (en) | 2018-11-07 |
| CN104797248B (zh) | 2017-10-31 |
| CN104797248A (zh) | 2015-07-22 |
| CA2884592C (en) | 2021-08-31 |
| US20210154160A1 (en) | 2021-05-27 |
| US20170333372A1 (en) | 2017-11-23 |
| AU2013318686B2 (en) | 2017-11-30 |
| KR102198633B1 (ko) | 2021-01-05 |
| EP2897604B1 (en) | 2018-07-04 |
| AU2013318686A1 (en) | 2015-04-02 |
| JP2015529245A (ja) | 2015-10-05 |
| US20240065993A1 (en) | 2024-02-29 |
| EP2897604A1 (en) | 2015-07-29 |
| DK2897604T3 (en) | 2018-08-06 |
| CA2884592A1 (en) | 2014-03-27 |
| ES2681343T3 (es) | 2018-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1212701A1 (zh) | 恩雜魯胺製劑 | |
| EP2917314A4 (en) | OLIGOMERATZUSAMMENSETZUNG | |
| HK1215165A1 (zh) | 組合物 | |
| HK1207566A1 (en) | Compositions for improvement of brain function | |
| HK1210019A1 (en) | Chitosan-derived compositions | |
| HK1208354A1 (en) | Compositions | |
| IL236312A0 (en) | Preparation of 18f-flucyclobin | |
| GB201210800D0 (en) | Compositions | |
| GB201209244D0 (en) | Compositions | |
| GB201201287D0 (en) | Compositions | |
| ZA201502350B (en) | Solid form of hihydro-pyrido-oxazine derivative | |
| ZA201503102B (en) | Finafloxacin suspension compositions | |
| GB201220068D0 (en) | Compositions | |
| GB201318407D0 (en) | Compositions | |
| GB201219962D0 (en) | Compositions | |
| GB201219973D0 (en) | Compositions | |
| GB201219980D0 (en) | Compositions | |
| LT2928896T (lt) | Dihidro-pirido-oksazino darinio kieta forma | |
| EP2926813A4 (en) | METFORMIN-Orlistat COMPOSITIONS | |
| GB201223148D0 (en) | Compositions | |
| GB201222702D0 (en) | Compositions | |
| GB201218959D0 (en) | Compositions | |
| GB201209189D0 (en) | Compositions | |
| GB201209187D0 (en) | Compositions | |
| GB201204103D0 (en) | Compositions |